Announced Fri, 29 May · 22:24 IST

Detailed disclosure is attached

Revenue DeclinePat Growth 25pctExceptional ItemResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹35.25
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.6-0.7-0.7+2.0+1.8-2.0-3.4+3.3
Up moveDown movePending
AI summary

Gujarat Terce Laboratories reported annual revenue of Rs. 4,747.27 lakhs for FY2026, down from Rs. 5,019.52 lakhs in FY2025, representing a revenue decline of about 5.4%. Despite lower revenue, the company turned profitable with PAT of Rs. 220.17 lakhs compared to a net loss of Rs. 97.87 lakhs in the previous year. An exceptional item of Rs. 45.39 lakhs was recorded due to a one-time provision for employee benefits arising from India's New Labour Codes. The statutory auditor issued an unmodified (clean) opinion on the financial statements. Cash flow from operations remained positive at Rs. 171.47 lakhs, and the company's cash position improved significantly to Rs. 285.98 lakhs from Rs. 77.94 lakhs.

Likely market impact

The company successfully returned to profitability despite revenue decline, though the top-line contraction may concern growth-focused investors. The clean audit opinion and strong cash generation are positives for shareholders.